Limits...
Correction: Economic Analysis of Vaccination Strategies for PRRS Control.

Linhares DC, Johnson C, Morrison RB - PLoS ONE (2016)

View Article: PubMed Central - PubMed

No MeSH data available.


Related in: MedlinePlus

Break-even analysis of preventive vaccination practice according to cost of attenuated-PRRSv on growth performance or magnitude of reduction on pigs/sow/year (PSY) due to attenuated PRRSv.(A) Impact of margin over variable cost (MOVC) and production cost attributable to PRRSv on advantage to have prior PRRSv-immunity. (B) Impact of MOVC and PSY on advantage to have prior PRRSv-immunity.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4835049&req=5

pone.0150444.g003: Break-even analysis of preventive vaccination practice according to cost of attenuated-PRRSv on growth performance or magnitude of reduction on pigs/sow/year (PSY) due to attenuated PRRSv.(A) Impact of margin over variable cost (MOVC) and production cost attributable to PRRSv on advantage to have prior PRRSv-immunity. (B) Impact of MOVC and PSY on advantage to have prior PRRSv-immunity.

Mentions: There are errors in Figs 3–5. Please see the corrected Figs 3–5 below.


Correction: Economic Analysis of Vaccination Strategies for PRRS Control.

Linhares DC, Johnson C, Morrison RB - PLoS ONE (2016)

Break-even analysis of preventive vaccination practice according to cost of attenuated-PRRSv on growth performance or magnitude of reduction on pigs/sow/year (PSY) due to attenuated PRRSv.(A) Impact of margin over variable cost (MOVC) and production cost attributable to PRRSv on advantage to have prior PRRSv-immunity. (B) Impact of MOVC and PSY on advantage to have prior PRRSv-immunity.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4835049&req=5

pone.0150444.g003: Break-even analysis of preventive vaccination practice according to cost of attenuated-PRRSv on growth performance or magnitude of reduction on pigs/sow/year (PSY) due to attenuated PRRSv.(A) Impact of margin over variable cost (MOVC) and production cost attributable to PRRSv on advantage to have prior PRRSv-immunity. (B) Impact of MOVC and PSY on advantage to have prior PRRSv-immunity.
Mentions: There are errors in Figs 3–5. Please see the corrected Figs 3–5 below.

View Article: PubMed Central - PubMed

No MeSH data available.


Related in: MedlinePlus